Total Return chart Myriad Genetics, Inc.

Stocks

Market Closed - Nasdaq 00:00:00 16/10/2026 +04			5-day change	1st Jan Change
4.350 ^USD	+4.82%		+1.64%	-29.27%

10-08	Sophia Genetics, Myriad Genetics Collaborate on Prostate Cancer Biomarker	MT
10-08	Myriad Genetics, Inc. and SOPHiA GENETICS Announce Collaboration to Advance Prostate Genomic Instability Score Technology with AstraZeneca	CI

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.